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Abstract
Background: Considerable technological advancements have recently been made with endovascular stent
grafts for the treatment of abdominal aortic aneurysm (AAA). However, there is opportunity to further improve
the efficiency of endovascular aneurysm repair (EVAR), which may yield better patient outcomes and lower
perioperative treatment costs.
Methods/Design: The Least Invasive Fast-Track EVAR (LIFE) registry was developed to determine the clinical
utility and cost effectiveness of the Ovation® Prime stent graft when used under least invasive conditions using
a defined fast-track protocol. The LIFE study is a prospective multicenter post-market registry of the ultra-low
profile (14F) Ovation Prime stent graft when used in the treatment of patients with AAA using a fast-track
protocol, consisting of appropriate patient selection, bilateral percutaneous access, avoidance of general
anesthesia and intensive care unit admission, and next-day discharge. The primary endpoint of the study is the
proportion of subjects that experience a major adverse event within 30 days of the initial procedure. Primary
endpoint data will be compared to a target performance goal. A total of 250 subjects will be enrolled at up to
40 sites in the United States. The first subject in this study was enrolled in October 2014 and enrollment is
anticipated to continue through mid-2016.
Discussion: The recent development of ultra low-profile stent grafts enables EVAR using least invasive
methods. A structured fast-track EVAR protocol may yield clinical and cost benefits versus standard EVAR.
Trial registration: ClinicalTrials.gov Identifier: NCT02224794
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Background
Over the last decade, considerable advancements have
been made with endovascular stent grafts for the treat-
ment of abdominal aortic aneurysm (AAA). Early studies
with endovascular aortic repair (EVAR) demonstrated
significantly lower perioperative morbidity and mortality
rates compared to open surgical resection [1]. Conse-
quently, EVAR has rapidly become the standard of care for
AAA repair at most centers. Studies with latest-generation
stent grafts have focused on improving treatment durability
and expanding EVAR eligibility to accommodate patients
with challenging aortoiliac anatomy. Despite this recent
progress, considerable opportunity exists to further im-
prove the efficiency of EVAR, which may yield even better
patient outcomes and lower perioperative treatment costs.
Typical EVAR cases involve vascular access via surgical
exposure of the common femoral artery, general anesthesia,
a 24-h intensive care unit (ICU) stay, and a 3-day
hospitalization [2], all of which increase morbidity and
significantly contribute to the total cost of EVAR. In
the current economic climate, there is heightened scrutiny
on health care resource utilization such that opportunities
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for improved surgical- and hospital-related efficiency must
continue to be explored. Fast-track hospital care pathways
have been adopted with increasing frequency for open
aortic surgery, resulting in shorter ICU [3, 4] and hospital
[5, 6] stays with reductions in morbidity [3, 4, 6] compared
to traditional surgical practices. However, experience with
fast-track EVAR remains limited. The common premise
of fast-track EVAR includes well-selected patients with
low-risk of periprocedural complications, bilateral per-
cutaneous vascular access, and regional anesthesia with
or without conscious sedation, all of which enable faster pa-
tient recovery and expedite hospital discharge. The largest
study of fast-track EVAR involved 915 patients treated with
bilateral percutaneous access and local anesthesia/con-
scious sedation [7]. Treatment success was achieved in
94 % of cases, mean hospital stay was 1.3 days, and 30-day
mortality was only 0.6 %. The clinical and cost benefits as-
sociated with fast-track EVAR are potentially substantial,
but currently are not well characterized. The Least In-
vasive Fast-Track EVAR (LIFE) registry was developed
to explore the clinical utility and cost effectiveness of a
defined fast-track EVAR protocol in patients undergoing
elective AAA repair.
Methods/Design
The LIFE registry is a prospective, nonrandomized, mul-
ticenter post-market study that will enroll 250 patients
at up to 40 sites in the United States. The protocol for
this clinical trial has been approved by the institutional
review board (IRB) at each participating site. Recruit-
ment is ongoing and additional sites, up to 40 total sites,
will be added to those already named in Table 1. All pa-
tients provided informed consent before study participa-
tion. Patient enrollment began in October 2014. This
study was prospectively registered at www.clinicaltrials.gov
(NCT02224794).
Participants
Eligible patients are adults with AAA requiring elective
intervention who have anatomy suitable for endovascular
repair. Complete inclusion and exclusion criteria are re-
ported in Table 2. Pre-treatment assessments will include
medical and surgical history, laboratory tests for creatinine
and pregnancy, spiral contrast-enhanced computed tomog-
raphy, and questionnaires related to groin pain severity and
health-related quality of life. Patients will be enrolled and
treated with EVAR if the investigator determines that bilat-
eral percutaneous access, avoidance of general anesthesia
and ICU stay, and next-day hospital discharge are feasible
based on medical history and aortoiliac anatomy. Following
enrollment, patients will remain in the study regardless of
whether all components of the fast-track program are com-
pleted. Patient outcomes will be recorded through hospital
discharge and at the 30-day follow-up visit per the schedule
of activities in Table 3.
Device
The endograft under study is ideally suited for use in a
fast-track EVAR program. The Ovation Prime stent graft
is characterized by a tri-modular design with the aortic
Table 1 Study Sites and Institutional Review Board
Site Name Institutional Review Board
Central Arkansas Veterans
Healthcare System
Central Arkansas Veterans Healthcare
System IRB
NCH Healthcare Systems NCH IRB
Temple University Hospital WIRB
Wellmont Holston Valley MC Wellmont Health System IRB
Morton Plant Hospital BayCare Health System IRB
Swedish Heart and Vascular WIRB
Bend Memorial Clinic WIRB
Hartford Hospital Hartford Health Care IRB
WVU Hospital West Virginia University IRB
St. Luke’s Episcopal Hospital BRANY IRB
Palomar Medical Center WIRB
SIH Memorial Hospital SIH IRB
Sutter Memorial Hospital WIRB
Chandler Regional Medical Center East Valley Regional IRB
Syracuse VA Medical Center Syracuse VAMC IRB
Southern Ohio Medical Center Southern Ohio Medical Center IRB
Jersey Shore University Medical
Center
WIRB
St. Joseph Mercy Oakland St. Joseph Mercy IRB
Phoenix St. Luke‘s Medical Center WIRB
Medical University of South
Carolina
MUSC IRB III
OhioHealth Research Institute WIRB
Arizona Heart Institute WIRB
Heart Hospital of New Mexico WIRB
Tuscon Medical Center WIRB
Harrison Medical Center WIRB and Harrison Medical Center IRB
Bakersfield Heart Hospital WIRB
Saint Jospeh Hospital WIRB
Lutheran Medical Center Lutheran Medical Center IRB
Middlesex Hospital Middlesex Hospital IRB
Sacred Heart Hospital Sacred Heart Clinical IRB
Memorial Hospital of Jacksonville
(FCCI)
WIRB
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body delivered via a flexible hydrophilic-coated 14 Fr
OD catheter, the smallest profile of any currently commer-
cially available stent grafts. The aortic body is comprised of
a low permeability PTFE graft and a suprarenal nitinol
stent with integral anchors to achieve active fixation to
the aortic wall. The aortic body contains a network of
inflatable channels and sealing rings that are filled dur-
ing deployment with a low viscosity, radiopaque fill
polymer that cures in situ to create a conformable seal
to the aortic neck. The Ovation Prime iliac limbs are
comprised of highly flexible nitinol stents encapsulated
in low-permeability PTFE that are packaged in ultra-low
profile 13-14F OD delivery system.
Outcomes
The primary endpoint of the LIFE registry is the incidence
of major adverse events through 30 days follow-up. Major
adverse events are defined as any of the following events:
death, myocardial infarction, stroke, renal failure, respira-
tory failure, paralysis, bowel ischemia, or procedural blood
loss ≥ 1000 cc. All adverse events will be adjudicated by a
Clinical Events Committee (CEC). Secondary endpoints of
the LIFE registry include operative details, technical suc-
cess, procedure- and device-related complications, patient
convalescence, and ability to successfully complete all
components of the fast-track protocol (Table 4). Patients
will be followed in the LIFE registry for 30 days post-
treatment and will undergo lifelong surveillance thereafter.
A 30-day primary endpoint is appropriate since the benefits
of a fast-track EVAR program are anticipated to be realized
entirely in the perioperative period.
Hypothesis
The primary hypothesis of the LIFE registry is that the
incidence of major adverse events through 30 days will
be less than a target performance goal (TPG) of 10.4 %.
The TPG was determined by using the 95 % upper-
bound confidence interval of the 30-day major adverse
event rate in the Ovation® pivotal trial (5.4 %) [8] and
adding a 5 % margin.
Table 2 Main study entry criteria
Main inclusion criteria
− Age≥ 18 years
− Male or non-pregnant female
− Candidate for elective open surgical AAA repair
− AAA >5.0 cm diameter, increased≥ 0.5 cm diameter in last 6 months,
or maximum diameter > 1.5x adjacent non-aneurysmal aorta
− Suitable anatomy for endovascular repair with the Ovation Prime
Stent Graft
− Suitable anatomy to allow Perclose ProGlide Suture-Mediated
Closure System via the pre-close technique
Main exclusion criteria
− Dissecting or acutely ruptured AAA
− Acute vascular injury
− Prior AAA or iliac artery repair
− Mycotic AAA or active systemic infection
− Unstable angina
− Unstable peripheral artery disease with critical limb ischemia
− Congestive heart failure
− Myocardial infarction or stroke within the past 3 months
− Need for renal artery coverage (e.g. Chimney graft)
− Planned adjunctive devices (e.g. renal stent)
− Major surgery or interventional procedure within the past 30 days
− Connective tissue disease (e.g. Marfan’s or Ehler’s–Danlos syndrome)
− History of bleeding disorder or refuses blood transfusions
− Dialysis-dependent renal failure or serum creatinine >2.0 mg/dl
− Morbid obesity (BMI ≥40 kg/m2)
− Home oxygen use
− Patient admitted from skilled nursing facility
− Life expectancy < 1 year
− Anticipated inability to discharge patient within 1 day
− Participation in investigational device or drug clinical trial
− Intolerance/hypersensitivity to anticoagulation, contrast media, or
stent graft components
Table 3 Schedule of study activities
Procedure Baseline Procedure Post-Procedure 1 Month
Medical/surgical history X
Spiral contrast-enhanced CT X X
Laboratory assessment (creatinine, serum pregnancy) X
Quality of life (EQ-5D) X X
Groin pain (Wong-Baker FACES Pain Rating Scale) X X X
Endovascular AAA repair X
Adverse events X X X
Assessment of ambulation and normal diet X
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Statistical methods
The sample size for the LIFE registry was determined
using the exact binomial method based on a one-sided
5 % significance level, an anticipated 5 % major adverse
event rate, and no more than 20 % attrition. Based on
these assumptions, a sample size of 250 subjects pro-
vides at least 87 % power to test the primary hypothesis.
Intent-to-treat analyses will be performed, which include
all patients enrolled in the registry regardless of whether
the fast-track protocol is completed successfully. Subjects
will be considered enrolled when the delivery catheter is
inserted into the vasculature. Continuous data will be re-
ported using mean and standard deviation or median,
minimum, and maximum, depending on normality as-
sumptions. Categorical data will be reported with counts
and percentages. The incidence of major adverse events
will be compared to the TPG by calculating a one-sided
95 % Wilson upper confidence interval limit. Subgroup
analyses will be performed for: a) patients who complete
the fast-track EVAR protocol, b) patients who undergo bi-
lateral percutaneous access but do not complete the fast-
track EVAR protocol, and c) patients who do not undergo
bilateral percutaneous access.
Study progress
The first patient in this study was enrolled in October
2014 and enrollment is anticipated to continue through
mid-2016. As of October 4, 2015, 149 patients have been
enrolled at over 25 sites in the United States.
Discussion
The recent development of ultra low-profile stent grafts
enables EVAR using least invasive methods. However, strict
patient selection criteria are crucial to improving outcomes
of a fast-track EVAR program. Ideal candidates have access
vessels free of heavy calcification or extreme tortuosity and
have no major risk factors for prolonged procedure or
hospitalization such as ruptured AAA, renal failure, and se-
vere comorbid conditions. Bilateral percutaneous vascular
access results in higher technical success, less blood loss,
fewer complications, and shorter hospital stay compared to
surgical cutdown [7, 9–15]. Avoidance of general anesthesia
is associated with lower rates of mortality and morbidity
and shorter intensive care unit and hospital stays compared
to regional anesthesia [16]. Next-day hospital discharge
with no ICU stay has obvious cost benefits, provided
that patient safety is not compromised. The observed
advantages of each separate component may potentially
yield synergistic clinical and cost benefits when utilized
collectively in a structured fast-track EVAR protocol.
The results of the LIFE study with the Ovation Prime stent
graft are anticipated to be available in late 2016.
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Table 4 Secondary endpoints
− Serious and non-serious adverse events
− Access technical success (i.e. procedure successfully completed with
bilateral percutaneous access)
− Treatment success (i.e. successful completion of least invasive protocol
through discharge)
− Blood loss, including if transfusion required





− Time to hemostasis
− Time to ambulation
− Time to normal diet
− Groin pain
− Quality of life
− Percent of subjects discharged without ICU admission
− Length of ICU stay, if required
− Length of hospital stay
− Percent of subjects discharged within only one overnight stay
− Freedom from type I & III endoleak
− Freedom from AAA rupture
− Freedom from conversion to open repair
− Freedom from AAA-related secondary interventions
− Freedom from mortality
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